Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 6/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | ITK | Q08881 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 7/20 | 0.36 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.36 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.36 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26644879 | 1.00 | JAK3 (0.43) | JAK3EGFRITKBTKCSNK1D | |
| SCHEMBL26644925 | 0.92 | CSNK1E (0.46) | JAK3EGFRITKBTKCSNK1D | |
| SCHEMBL30622339 | 0.92 | CSNK1E (0.46) | JAK3EGFRITKBTKCSNK1D | |
| SCHEMBL30622428 | 0.91 | JAK3 (0.45) | JAK3EGFRBTKCSNK1DCSNK1E | |
| SCHEMBL26644977 | 0.91 | JAK3 (0.45) | JAK3EGFRBTKCSNK1DCSNK1E | |
| SCHEMBL30622345 | 0.90 | JAK3 (0.45) | JAK3EGFRBTK | |
| SCHEMBL26644982 | 0.90 | JAK3 (0.45) | JAK3EGFRBTK | |
| SCHEMBL30622404 | 0.89 | JAK3 (0.41) | JAK3BTKCSNK1DCSNK1E | |
| SCHEMBL26644850 | 0.89 | JAK3 (0.41) | JAK3BTKCSNK1DCSNK1E | |
| SCHEMBL30622424 | 0.88 | JAK3 (0.44) | JAK3ITKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | claimed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | claimed |
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | disclosed |